{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:10:11Z","timestamp":1792239011163,"version":"4.4.0"},"reference-count":213,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes &amp; Diseases"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.gendis.2023.101150","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T11:45:11Z","timestamp":1698320711000},"page":"101150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia"],"prefix":"10.1016","volume":"11","author":[{"given":"Xudong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.gendis.2023.101150_bib1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jama.286.8.895","article-title":"Chronic myelogenous leukemia","volume":"286","author":"Kalidas","year":"2001","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.gendis.2023.101150_bib2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.gendis.2023.101150_bib3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gendis.2023.101150_bib4","doi-asserted-by":"crossref","first-page":"580759","DOI":"10.3389\/fonc.2020.580759","article-title":"Global, regional, and national burden of chronic myeloid leukemia, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"10","author":"Lin","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2023.101150_bib5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.gendis.2023.101150_bib6","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.gendis.2023.101150_bib7","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.2021011722","article-title":"How I treat chronic-phase chronic myelogenous leukemia","volume":"139","author":"Berman","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.gendis.2023.101150_bib8","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.2021014689","article-title":"Asciminib: a new therapeutic option in chronic-phase CML with treatment failure","volume":"139","author":"Yeung","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gendis.2023.101150_bib10","doi-asserted-by":"crossref","first-page":"100971","DOI":"10.1016\/j.blre.2022.100971","article-title":"Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML","volume":"56","author":"Drula","year":"2022","journal-title":"Blood Rev"},{"issue":"12","key":"10.1016\/j.gendis.2023.101150_bib11","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/1078155219864640","article-title":"Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: practice considerations","volume":"26","author":"Reff","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.gendis.2023.101150_bib15","doi-asserted-by":"crossref","first-page":"100825","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges, and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"issue":"7","key":"10.1016\/j.gendis.2023.101150_bib16","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.drudis.2019.05.007","article-title":"Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options","volume":"24","author":"Meenakshi Sundaram","year":"2019","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","article-title":"Olverembatinib: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"issue":"suppl 1","key":"10.1016\/j.gendis.2023.101150_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2021-153065","article-title":"Updated safety and efficacy results of phase 1 study of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML)","volume":"138","author":"Qian","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.gendis.2023.101150_bib19","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2021-153937","article-title":"Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1T315I-mutated chronic- and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP)","volume":"138","author":"Qian","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib20","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1111\/bjh.17068","article-title":"Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing","volume":"191","author":"Chen","year":"2020","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.gendis.2023.101150_bib21","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","article-title":"Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways","volume":"52","author":"Tang","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib22","doi-asserted-by":"crossref","first-page":"E903","DOI":"10.3390\/cancers12040903","article-title":"Role of DNA damage response in suppressing malignant progression of chronic myeloid leukemia and polycythemia vera: impact of different oncogenes","volume":"12","author":"Stetka","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib23","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3390\/ijms21041177","article-title":"DNA damage and DNA damage response in chronic myeloid leukemia","volume":"21","author":"Popp","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"suppl 1","key":"10.1016\/j.gendis.2023.101150_bib24","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1182\/blood-2021-154273","article-title":"Mutational profiles during the progression of chronic myeloid leukemia","volume":"138","author":"Xue","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.gendis.2023.101150_bib25","doi-asserted-by":"crossref","first-page":"6312","DOI":"10.1002\/jcp.30301","article-title":"PKC-\u03b2\/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia","volume":"236","author":"Ma","year":"2021","journal-title":"J Cell Physiol"},{"issue":"19","key":"10.1016\/j.gendis.2023.101150_bib26","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia - from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.gendis.2023.101150_bib27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/leu.2016.51","article-title":"A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"30","author":"Wagle","year":"2016","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.gendis.2023.101150_bib28","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood-2021-147954","article-title":"Second treatment free remission after combination therapy with ruxolitinib plus tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia (CML)","volume":"138","author":"Sweet","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib29","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/sctm.17-0175","article-title":"Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment","volume":"7","author":"Arrigoni","year":"2018","journal-title":"Stem Cells Transl Med"},{"issue":"7281","key":"10.1016\/j.gendis.2023.101150_bib32","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"issue":"7607","key":"10.1016\/j.gendis.2023.101150_bib34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib35","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmet.2022.04.004","article-title":"Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML","volume":"34","author":"Liu","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.gendis.2023.101150_bib36","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1158\/1078-0432.CCR-16-0226","article-title":"Anthelmintic niclosamide disrupts the interplay of p65 and FOXM1\/\u03b2-catenin and eradicates leukemia stem cells in chronic myelogenous leukemia","volume":"23","author":"Jin","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2023.101150_bib37","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1038\/ncomms9039","article-title":"Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells","volume":"6","author":"Naka","year":"2015","journal-title":"Nat Commun"},{"issue":"S1","key":"10.1016\/j.gendis.2023.101150_bib38","first-page":"630","article-title":"Lysosomal acid lipase a (LIPA) modulates leukemia stem cell (LSC) response to venetoclax\/TKI combination therapy in blast phase chronic myeloid leukemia","volume":"138","author":"Mohd","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib39","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2010.04.003","article-title":"The bone marrow microenvironment as a sanctuary for minimal residual disease in CML","volume":"80","author":"Nair","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib40","doi-asserted-by":"crossref","first-page":"109386","DOI":"10.1016\/j.celrep.2021.109386","article-title":"TNF-\u03b1-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling","volume":"36","author":"Agarwal","year":"2021","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrc.2017.105","article-title":"Ubiquitin ligases in oncogenic transformation and cancer therapy","volume":"18","author":"Senft","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib42","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ncb3358","article-title":"The increasing complexity of the ubiquitin code","volume":"18","author":"Yau","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"5809","key":"10.1016\/j.gendis.2023.101150_bib43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1126\/science.1127085","article-title":"Proteasome-independent functions of ubiquitin in endocytosis and signaling","volume":"315","author":"Mukhopadhyay","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.gendis.2023.101150_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","article-title":"The ubiquitin code","volume":"81","author":"Komander","year":"2012","journal-title":"Annu Rev Biochem"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib45","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nsmb.2066","article-title":"Constructing and decoding unconventional ubiquitin chains","volume":"18","author":"Behrends","year":"2011","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrm2673","article-title":"Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways","volume":"10","author":"Schulman","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"10.1016\/j.gendis.2023.101150_bib47","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrm2767","article-title":"Ubiquitin-binding domains - from structures to functions","volume":"10","author":"Dikic","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib48","first-page":"168","article-title":"New insights into the role of E2s in the pathogenesis of diseases: lessons learned from UBE2O","volume":"41","author":"Hormaechea-Agulla","year":"2018","journal-title":"Mol Cells"},{"issue":"11","key":"10.1016\/j.gendis.2023.101150_bib49","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrm2780","article-title":"Building ubiquitin chains: E2 enzymes at work","volume":"10","author":"Ye","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib50","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1096\/fj.09-136259","article-title":"The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins","volume":"24","author":"van Wijk","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.gendis.2023.101150_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-biochem-060815-014922","article-title":"Ubiquitin ligases: structure, function, and regulation","volume":"86","author":"Zheng","year":"2017","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1042\/BJ20140006","article-title":"RBR E3 ubiquitin ligases: new structures, new insights, new questions","volume":"458","author":"Spratt","year":"2014","journal-title":"Biochem J"},{"issue":"8","key":"10.1016\/j.gendis.2023.101150_bib53","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.tcb.2022.02.005","article-title":"Quality control of protein complex assembly by the ubiquitin-proteasome system","volume":"32","author":"Pla-Prats","year":"2022","journal-title":"Trends Cell Biol"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.molcel.2021.10.027","article-title":"Deubiquitinases: from mechanisms to their inhibition by small molecules","volume":"82","author":"Lange","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.gendis.2023.101150_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-biochem-093010-153308","article-title":"Ubiquitin-like proteins","volume":"81","author":"van der Veen","year":"2012","journal-title":"Annu Rev Biochem"},{"issue":"9","key":"10.1016\/j.gendis.2023.101150_bib56","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.3390\/ijms23095053","article-title":"Ubiquitin and ubiquitin-like proteins in cancer, neurodegenerative disorders, and heart diseases","volume":"23","author":"Hwang","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib57","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/acs.chemrev.6b00737","article-title":"Ubiquitin-like protein conjugation: structures, chemistry, and mechanism","volume":"118","author":"Cappadocia","year":"2018","journal-title":"Chem Rev"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/cr.2016.39","article-title":"Ubiquitin modifications","volume":"26","author":"Swatek","year":"2016","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd.2017.152","article-title":"Deubiquitylating enzymes and drug discovery: emerging opportunities","volume":"17","author":"Harrigan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12964-017-0195-9","article-title":"DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway","volume":"15","author":"Bhattacharjee","year":"2017","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.gendis.2023.101150_bib61","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3389\/fimmu.2017.01187","article-title":"TRIM25 in the regulation of the antiviral innate immunity","volume":"8","author":"Mart\u00edn-Vicente","year":"2017","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.gendis.2023.101150_bib62","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.jmb.2017.10.001","article-title":"Ubiquitin-modifying enzymes and regulation of the inflammasome","volume":"429","author":"Kattah","year":"2017","journal-title":"J Mol Biol"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib63","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1021\/acsomega.1c04726","article-title":"P53: stability from the ubiquitin-proteasome system and specific 26S proteasome inhibitors","volume":"7","author":"do Patrocinio","year":"2022","journal-title":"ACS Omega"},{"issue":"11","key":"10.1016\/j.gendis.2023.101150_bib64","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.3390\/ijms22116107","article-title":"Molecular pathogenesis of pulmonary fibrosis, with focus on pathways related to TGF-\u03b2 and the ubiquitin-proteasome pathway","volume":"22","author":"Inui","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.gendis.2023.101150_bib65","doi-asserted-by":"crossref","first-page":"8902","DOI":"10.1021\/jacs.1c03852","article-title":"TF-PROTACs enable targeted degradation of transcription factors","volume":"143","author":"Liu","year":"2021","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib67","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/cr.2016.31","article-title":"Drugging the undruggables: exploring the ubiquitin system for drug development","volume":"26","author":"Huang","year":"2016","journal-title":"Cell Res"},{"issue":"7","key":"10.1016\/j.gendis.2023.101150_bib68","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"7239","key":"10.1016\/j.gendis.2023.101150_bib69","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib70","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.gendis.2023.101150_bib71","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.clml.2019.05.017","article-title":"Oprozomib, pomalidomide, and dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"19","author":"Shah","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.gendis.2023.101150_bib72","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1080\/10428194.2016.1263842","article-title":"Phase I\/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma","volume":"58","author":"Vogl","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.gendis.2023.101150_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biocel.2015.08.005","article-title":"p27(Kip1) signaling: transcriptional and post-translational regulation","volume":"68","author":"Hnit","year":"2015","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib74","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3390\/cells10051147","article-title":"Emerging roles of SKP2 in cancer drug resistance","volume":"10","author":"Wu","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.gendis.2023.101150_bib75","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/OTT.S125789","article-title":"Inhibition of Skp2 sensitizes lung cancer cells to paclitaxel","volume":"10","author":"Huang","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib76","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/jhep.2003.50186","article-title":"Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells","volume":"37","author":"Koga","year":"2003","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.gendis.2023.101150_bib77","first-page":"3819","article-title":"Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis","volume":"62","author":"Masuda","year":"2002","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib78","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2007-09-113860","article-title":"Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease","volume":"112","author":"Agarwal","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib79","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/jcp.22346","article-title":"Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells","volume":"226","author":"Chen","year":"2011","journal-title":"J Cell Physiol"},{"issue":"11","key":"10.1016\/j.gendis.2023.101150_bib80","doi-asserted-by":"crossref","first-page":"9815","DOI":"10.1074\/jbc.M110.165977","article-title":"SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27KIP1 through SKP2 in human leukemia cells","volume":"286","author":"Bretones","year":"2011","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/j.gendis.2023.101150_bib81","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/onc.2012.246","article-title":"MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.)","volume":"32","author":"G\u00f3mez-Casares","year":"2013","journal-title":"Oncogene"},{"issue":"33","key":"10.1016\/j.gendis.2023.101150_bib82","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1038\/onc.2014.364","article-title":"Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors","volume":"34","author":"Tomiatti","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2023.101150_bib83","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12967-016-0823-y","article-title":"Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells","volume":"14","author":"Iskandarani","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.gendis.2023.101150_bib84","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.2147\/CMAR.S253367","article-title":"Inhibition of Skp2 sensitizes chronic myeloid leukemia cells to imatinib","volume":"12","author":"Chen","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib85","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2007-01-066076","article-title":"Flt3-dependent transformation by inactivating c-Cbl mutations in AML","volume":"110","author":"Sargin","year":"2007","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.gendis.2023.101150_bib86","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib87","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2006-12-061176","article-title":"Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia","volume":"110","author":"Caligiuri","year":"2007","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.gendis.2023.101150_bib88","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","article-title":"250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies","volume":"68","author":"Dunbar","year":"2008","journal-title":"Cancer Res"},{"issue":"7257","key":"10.1016\/j.gendis.2023.101150_bib89","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2023.101150_bib90","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0145-2126(13)70023-7","article-title":"O-001 Clinical and biological implications of gene mutations in MDS","volume":"37","author":"Papaemmanuil","year":"2013","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib91","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.gendis.2023.101150_bib92","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.gendis.2023.101150_bib93","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.gendis.2023.101150_bib94","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","volume":"114","author":"Loh","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.gendis.2023.101150_bib95","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.gendis.2023.101150_bib96","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2008.001149","article-title":"The fusion proteins TEL-PDGFR\u03b2 and FIP1L1-PDGFR\u03b1 escape ubiquitination and degradation","volume":"94","author":"Toffalini","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.gendis.2023.101150_bib97","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1073\/pnas.0813280106","article-title":"Long-term efficacy and safety of all-trans retinoic acid\/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia","volume":"106","author":"Hu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.gendis.2023.101150_bib98","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1182\/blood-2004-04-1433","article-title":"Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein","volume":"104","author":"Yin","year":"2004","journal-title":"Blood"},{"issue":"50","key":"10.1016\/j.gendis.2023.101150_bib99","doi-asserted-by":"crossref","first-page":"21683","DOI":"10.1073\/pnas.1016311108","article-title":"As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia","volume":"107","author":"Mao","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.gendis.2023.101150_bib100","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood-2016-06-724658","article-title":"Acquired expression of CblQ367P in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia","volume":"129","author":"Nakata","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.gendis.2023.101150_bib101","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood.2020006528","article-title":"CBL mutations drive PI3K\/AKT signaling via increased interaction with LYN and PIK3R1","volume":"137","author":"Belizaire","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.gendis.2023.101150_bib102","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2010-10-313692","article-title":"Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells","volume":"118","author":"Gioia","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib103","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/path.4561","article-title":"CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia","volume":"237","author":"Gioia","year":"2015","journal-title":"J Pathol"},{"issue":"10","key":"10.1016\/j.gendis.2023.101150_bib104","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1101\/gad.297135.117","article-title":"CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies","volume":"31","author":"Lv","year":"2017","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib105","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/ncb3121","article-title":"FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification","volume":"17","author":"Kourtis","year":"2015","journal-title":"Nat Cell Biol"},{"issue":"13","key":"10.1016\/j.gendis.2023.101150_bib106","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1158\/0008-5472.CAN-16-3470","article-title":"Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer","volume":"77","author":"Ye","year":"2017","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.gendis.2023.101150_bib107","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2018-09-874529","article-title":"FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL","volume":"133","author":"Close","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib108","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.celrep.2019.12.032","article-title":"FBXW7 confers radiation survival by targeting p53 for degradation","volume":"30","author":"Cui","year":"2020","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.gendis.2023.101150_bib109","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1101\/gad.1621808","article-title":"Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL","volume":"22","author":"Matsuoka","year":"2008","journal-title":"Genes Dev"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib110","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.20080277","article-title":"Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7","volume":"205","author":"Thompson","year":"2008","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib111","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ceb.2009.09.006","article-title":"Myc's other life: stem cells and beyond","volume":"21","author":"Laurenti","year":"2009","journal-title":"Curr Opin Cell Biol"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib112","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ni.1839","article-title":"Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex","volume":"11","author":"Reavie","year":"2010","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib113","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ccr.2013.01.025","article-title":"Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression","volume":"23","author":"Reavie","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib114","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2013.01.026","article-title":"Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence","volume":"23","author":"Takeishi","year":"2013","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib115","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1128\/MCB.19.6.4535","article-title":"Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions","volume":"19","author":"Ballinger","year":"1999","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib116","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1379\/1466-1268(2003)008<0303:CALBTC>2.0.CO;2","article-title":"CHIP: a link between the chaperone and proteasome systems","volume":"8","author":"McDonough","year":"2003","journal-title":"Cell Stress Chaperones"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib117","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1357-2725(02)00394-1","article-title":"CHIP: a quality-control E3 ligase collaborating with molecular chaperones","volume":"35","author":"Murata","year":"2003","journal-title":"Int J Biochem Cell Biol"},{"issue":"18","key":"10.1016\/j.gendis.2023.101150_bib118","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2009-10-249623","article-title":"Bag1 directly routes immature BCR-ABL for proteasomal degradation","volume":"116","author":"Tsukahara","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.gendis.2023.101150_bib119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.leukres.2017.11.007","article-title":"Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells","volume":"64","author":"Lei","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.gendis.2023.101150_bib120","doi-asserted-by":"crossref","first-page":"28352","DOI":"10.1038\/srep28352","article-title":"The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL","volume":"6","author":"Ru","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.gendis.2023.101150_bib121","first-page":"146028","article-title":"The role of Siah2 in tumorigenesis and cancer therapy","author":"Li","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.gendis.2023.101150_bib122","doi-asserted-by":"crossref","first-page":"727","DOI":"10.12659\/MSM.908553","article-title":"Inhibition of Siah2 ubiquitin ligase by vitamin K3 attenuates chronic myeloid leukemia chemo-resistance in hypoxic microenvironment","volume":"24","author":"Huang","year":"2018","journal-title":"Med Sci Monit"},{"issue":"22","key":"10.1016\/j.gendis.2023.101150_bib123","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.2018875922","article-title":"A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells","volume":"134","author":"Park","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.gendis.2023.101150_bib124","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1080\/15548627.2022.2047384","article-title":"TRAF6 autophagic degradation by avibirnavirus VP3 inhibits antiviral innate immunity via blocking NFKB\/NF-\u03baB activation","volume":"18","author":"Deng","year":"2022","journal-title":"Autophagy"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib125","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/hep.32179","article-title":"OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways","volume":"75","author":"Zhang","year":"2022","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib126","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/15548627.2021.1965421","article-title":"Increased alveolar epithelial TRAF6 via autophagy-dependent TRIM37 degradation mediates particulate matter-induced lung metastasis","volume":"18","author":"Liu","year":"2022","journal-title":"Autophagy"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib127","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.stem.2021.12.007","article-title":"TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity","volume":"29","author":"Muto","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"12","key":"10.1016\/j.gendis.2023.101150_bib128","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1080\/15548627.2019.1596492","article-title":"GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia","volume":"15","author":"Han","year":"2019","journal-title":"Autophagy"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3390\/cancers13020341","article-title":"The giant HECT E3 ubiquitin ligase HERC1 is aberrantly expressed in myeloid related disorders and it is a novel BCR-ABL1 binding partner","volume":"13","author":"Ali","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib130","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/jcm11020324","article-title":"The downregulation of both giant HERCs, HERC1 and HERC2, is an unambiguous feature of chronic myeloid leukemia, and HERC1 levels are associated with leukemic cell differentiation","volume":"11","author":"Ali","year":"2022","journal-title":"J Clin Med"},{"issue":"6419","key":"10.1016\/j.gendis.2023.101150_bib131","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.aap8210","article-title":"LZTR1 is a regulator of RAS ubiquitination and signaling","volume":"362","author":"Bigenzahn","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib132","doi-asserted-by":"crossref","first-page":"E595","DOI":"10.3390\/cells9030595","article-title":"Non-thermal plasma induces antileukemic effect through mTOR ubiquitination","volume":"9","author":"Kim","year":"2020","journal-title":"Cells"},{"issue":"15","key":"10.1016\/j.gendis.2023.101150_bib133","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-19-2460","article-title":"Discovery of berberine that targetedly induces autophagic degradation of both BCR-ABL and BCR-ABL T315I through recruiting LRSAM1 for overcoming imatinib resistance","volume":"26","author":"Yin","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2023.101150_bib134","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.freeradbiomed.2021.02.024","article-title":"H2O2 mediated FLIP and XIAP down-regulation involves increased ITCH expression and ERK-Akt crosstalk in imatinib resistant Chronic Myeloid Leukemia cell line K562","volume":"166","author":"Paul","year":"2021","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib135","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3892\/ijmm.2020.4634","article-title":"Exosomal microRNA-146a derived from mesenchymal stem cells increases the sensitivity of ovarian cancer cells to docetaxel and taxane via a LAMC2-mediated PI3K\/Akt axis","volume":"46","author":"Qiu","year":"2020","journal-title":"Int J Mol Med"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib136","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41419-022-04531-3","article-title":"HucMSC exosomes promoted imatinib-induced apoptosis in K562-R cells via a miR-145a-5p\/USP6\/GLS1 axis","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib137","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.7150\/ijbs.70960","article-title":"IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma","volume":"18","author":"Liu","year":"2022","journal-title":"Int J Biol Sci"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib138","doi-asserted-by":"crossref","first-page":"102435","DOI":"10.1016\/j.isci.2021.102435","article-title":"The USP7-TRIM27 axis mediates non-canonical PRC1.1 function and is a druggable target in leukemia","volume":"24","author":"Maat","year":"2021","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib139","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/leu.2013.370","article-title":"BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP","volume":"28","author":"Morotti","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.gendis.2023.101150_bib140","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41419-021-03732-6","article-title":"Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis","volume":"12","author":"Jiang","year":"2021","journal-title":"Cell Death Dis"},{"issue":"7","key":"10.1016\/j.gendis.2023.101150_bib141","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1038\/s41418-021-00740-z","article-title":"USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-\u03b22 transcription","volume":"28","author":"Jie","year":"2021","journal-title":"Cell Death Differ"},{"issue":"7","key":"10.1016\/j.gendis.2023.101150_bib142","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1002\/jcp.30763","article-title":"Deubiquitinating enzyme USP9X regulates metastasis and chemoresistance in triple-negative breast cancer by stabilizing Snail1","volume":"237","author":"Guan","year":"2022","journal-title":"J Cell Physiol"},{"issue":"7277","key":"10.1016\/j.gendis.2023.101150_bib143","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature08646","article-title":"Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival","volume":"463","author":"Schwickart","year":"2010","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.gendis.2023.101150_bib144","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood-2010-03-276477","article-title":"Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis","volume":"117","author":"Sun","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.gendis.2023.101150_bib145","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1093\/nar\/gkq1352","article-title":"USP10 deubiquitylates the histone variant H2A.Z and both are required for androgen receptor-mediated gene activation","volume":"39","author":"Draker","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"1\u20132","key":"10.1016\/j.gendis.2023.101150_bib146","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.mce.2005.11.011","article-title":"The ubiquitin-specific protease USP10 modulates androgen receptor function","volume":"245","author":"Faus","year":"2005","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib147","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2009.12.032","article-title":"USP10 regulates p53 localization and stability by deubiquitinating p53","volume":"140","author":"Yuan","year":"2010","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib148","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.celrep.2013.11.029","article-title":"USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation","volume":"5","author":"Lin","year":"2013","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib149","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.molcel.2016.01.010","article-title":"Deubiquitination and activation of AMPK by USP10","volume":"61","author":"Deng","year":"2016","journal-title":"Mol Cell"},{"issue":"12","key":"10.1016\/j.gendis.2023.101150_bib150","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/nchembio.2486","article-title":"Inhibition of USP10 induces degradation of oncogenic FLT3","volume":"13","author":"Weisberg","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.gendis.2023.101150_bib151","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41421-019-0092-z","article-title":"USP10 modulates the SKP2\/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia","volume":"5","author":"Liao","year":"2019","journal-title":"Cell Discov"},{"key":"10.1016\/j.gendis.2023.101150_bib152","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1038\/onc.2016.114","article-title":"A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy","volume":"35","author":"Zhao","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib153","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-016-0359-x","article-title":"Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr\/Abl-dependent and Bcr\/Abl-independent mechanisms","volume":"9","author":"Lan","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.gendis.2023.101150_bib154","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1038","article-title":"Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia","volume":"12","author":"Jiang","year":"2022","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.gendis.2023.101150_bib155","doi-asserted-by":"crossref","first-page":"115815","DOI":"10.1016\/j.jep.2022.115815","article-title":"Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells","volume":"301","author":"Lan","year":"2023","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib156","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.gendis.2023.101150_bib157","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1093\/nar\/gkn271","article-title":"In vivo identification of novel STAT5 target genes","volume":"36","author":"Basham","year":"2008","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"10.1016\/j.gendis.2023.101150_bib158","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1182\/blood-2011-01-332569","article-title":"STAT5 as a CML target: STATinib therapies?","volume":"117","author":"Turhan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.gendis.2023.101150_bib159","doi-asserted-by":"crossref","first-page":"8928","DOI":"10.1038\/ncomms9928","article-title":"STAT5-regulated microRNA-193b controls haematopoietic stem and progenitor cell expansion by modulating cytokine receptor signalling","volume":"6","author":"Haetscher","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13046-019-1502-7","article-title":"De-regulated STAT5A\/miR-202-5p\/USP15\/caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to imatinib resistance","volume":"39","author":"Nie","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.gendis.2023.101150_bib161","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1038\/s41388-020-1253-0","article-title":"Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells","volume":"39","author":"Shibata","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2023.101150_bib162","doi-asserted-by":"crossref","first-page":"172464","DOI":"10.1016\/j.ejphar.2019.172464","article-title":"LINC00668 promotes tumorigenesis and progression through sponging miR-188-5p and regulating USP47 in colorectal cancer","volume":"858","author":"Yan","year":"2019","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib163","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1038\/s41467-019-11093-0","article-title":"ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of \u03b2TrCP","volume":"10","author":"Bufalieri","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.gendis.2023.101150_bib164","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.canlet.2019.01.039","article-title":"Reversible regulation of SATB1 ubiquitination by USP47 and SMURF2 mediates colon cancer cell proliferation and tumor progression","volume":"448","author":"Yu","year":"2019","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib165","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41467-020-20259-0","article-title":"Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem\/progenitor cells in chronic myelogenous leukemia","volume":"12","author":"Lei","year":"2021","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.gendis.2023.101150_bib166","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1158\/0008-5472.CAN-07-0568","article-title":"Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib167","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/1087057111433843","article-title":"Identification and mechanistic studies of a novel ubiquitin E1 inhibitor","volume":"17","author":"Ungermannova","year":"2012","journal-title":"J Biomol Screen"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib168","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1158\/0008-5472.CAN-17-1733","article-title":"Antitumor effects of blocking protein neddylation in T315I-BCR-ABL leukemia cells and leukemia stem cells","volume":"78","author":"Liu","year":"2018","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.gendis.2023.101150_bib169","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1182\/blood.2020010400","article-title":"ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells","volume":"138","author":"Yang","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.gendis.2023.101150_bib170","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.3324\/haematol.2017.179937","article-title":"De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways","volume":"104","author":"Magistroni","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.gendis.2023.101150_bib171","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268352","article-title":"Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia","volume":"17","author":"Maletzke","year":"2022","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.gendis.2023.101150_bib172","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1158\/1078-0432.CCR-08-1953","article-title":"Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines","volume":"15","author":"Stein","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib173","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2141.2009.07875.x","article-title":"Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"147","author":"Vogl","year":"2009","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.gendis.2023.101150_bib174","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1038\/onc.2010.81","article-title":"Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in imatinib-sensitive and-resistant Bcr-Abl1-expressing cells","volume":"29","author":"Albero","year":"2010","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.gendis.2023.101150_bib175","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2008-06-164582","article-title":"Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD\/SCID repopulating cells","volume":"115","author":"Heaney","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib176","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2010.12.111","article-title":"Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR\/ABl+ cells sensitive and resistant to STI571 through down-regulation MCL-1","volume":"405","author":"Li","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.gendis.2023.101150_bib177","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077390","article-title":"Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells","volume":"8","author":"Bucur","year":"2013","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.gendis.2023.101150_bib178","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.gendis.2023.101150_bib179","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/nbt1112-1011","article-title":"Next-generation proteasome inhibitor approved in multiple myeloma","volume":"30","author":"Katsnelson","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib180","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1038\/oncsis.2014.3","article-title":"Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and-resistant chronic myeloid leukemia models","volume":"3","author":"Crawford","year":"2014","journal-title":"Oncogenesis"},{"issue":"9","key":"10.1016\/j.gendis.2023.101150_bib181","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.gendis.2023.101150_bib182","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.gendis.2023.101150_bib183","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood.V128.22.2110.2110","article-title":"Final results from a multicenter, open-label, dose-escalation phase 1b\/2 study of single-agent oprozomib in patients with hematologic malignancies","volume":"128","author":"Ghobrial Irene","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib184","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cas.14696","article-title":"Prolonged unfolded protein reaction is involved in the induction of chronic myeloid leukemia cell death upon oprozomib treatment","volume":"112","author":"Wang","year":"2021","journal-title":"Cancer Sci"},{"issue":"11","key":"10.1016\/j.gendis.2023.101150_bib185","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2217\/fon.12.131","article-title":"Targeting neddylation in cancer therapy","volume":"8","author":"Duncan","year":"2012","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.gendis.2023.101150_bib186","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2174\/1871520615666150305111257","article-title":"Neddylation pathway as a novel anti-cancer target: mechanistic investigation and therapeutic implication","volume":"15","author":"Jiang","year":"2015","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib187","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrm3919","article-title":"Protein neddylation: beyond cullin-RING ligases","volume":"16","author":"Enchev","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"24","key":"10.1016\/j.gendis.2023.101150_bib188","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1158\/1078-0432.CCR-15-0254","article-title":"NEDD8 inhibition overcomes CKS1B-induced drug resistance by upregulation of p21 in multiple myeloma","volume":"21","author":"Huang","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.gendis.2023.101150_bib189","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1080\/15384101.2019.1646068","article-title":"The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors","volume":"18","author":"Bahjat","year":"2019","journal-title":"Cell Cycle"},{"issue":"23","key":"10.1016\/j.gendis.2023.101150_bib190","doi-asserted-by":"crossref","first-page":"11315","DOI":"10.1016\/S0021-9258(18)60961-5","article-title":"Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin","volume":"262","author":"Haas","year":"1987","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib191","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood-2006-07-033209","article-title":"Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling","volume":"110","author":"Yan","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib192","first-page":"1","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib193","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib194","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib195","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"issue":"18","key":"10.1016\/j.gendis.2023.101150_bib196","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res"},{"issue":"50","key":"10.1016\/j.gendis.2023.101150_bib197","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1039\/D0CC02201B","article-title":"Scaffold hopping enables direct access to more potent PROTACs with in vivo activity","volume":"56","author":"Burslem","year":"2020","journal-title":"Chem Commun (Camb)"},{"issue":"9","key":"10.1016\/j.gendis.2023.101150_bib198","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1021\/acs.jmedchem.9b02058","article-title":"Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown","volume":"63","author":"Jin","year":"2020","journal-title":"J Med Chem"},{"issue":"15","key":"10.1016\/j.gendis.2023.101150_bib199","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1021\/acs.jmedchem.0c00967","article-title":"Global PROTAC toolbox for degrading BCR-ABL overcomes drug-resistant mutants and adverse effects","volume":"63","author":"Yang","year":"2020","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.gendis.2023.101150_bib200","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1021\/acs.jmedchem.9b01264","article-title":"Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von hippel-lindau (VHL) E3 ubiquitin ligase","volume":"62","author":"Zhao","year":"2019","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.gendis.2023.101150_bib201","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/cas.13284","article-title":"Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands","volume":"108","author":"Shibata","year":"2017","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.gendis.2023.101150_bib202","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1021\/acsmedchemlett.7b00247","article-title":"Targeting the allosteric site of oncoprotein BCR-ABL as an alternative strategy for effective target protein degradation","volume":"8","author":"Shimokawa","year":"2017","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"10.1016\/j.gendis.2023.101150_bib203","doi-asserted-by":"crossref","first-page":"13549","DOI":"10.1038\/s41598-018-31913-5","article-title":"Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase","volume":"8","author":"Shibata","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib204","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib205","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.molcel.2019.07.013","article-title":"Plasticity of the cullin-RING ligase repertoire shapes sensitivity to ligand-induced protein degradation","volume":"75","author":"Mayor-Ruiz","year":"2019","journal-title":"Mol Cell"},{"issue":"10","key":"10.1016\/j.gendis.2023.101150_bib206","first-page":"2215","article-title":"Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway","volume":"14","author":"Ottis","year":"2019","journal-title":"ACS Chem Biol"},{"issue":"7","key":"10.1016\/j.gendis.2023.101150_bib207","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.gendis.2023.101150_bib208","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.gendis.2023.101150_bib209","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1074-7613(01)00154-6","article-title":"Interferons alpha and beta as immune regulators: a new look","volume":"14","author":"Biron","year":"2001","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib210","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tcb.2022.06.010","article-title":"Targeting STING to promote antitumor immunity","volume":"33","author":"Chin","year":"2023","journal-title":"Trends Cell Biol"},{"issue":"10","key":"10.1016\/j.gendis.2023.101150_bib211","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.gendis.2023.101150_bib212","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.gendis.2023.101150_bib213","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2005.05606.x","article-title":"Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors","volume":"130","author":"Angstreich","year":"2005","journal-title":"Br J Haematol"}],"container-title":["Genes &amp; Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304223004336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304223004336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T02:45:34Z","timestamp":1719542734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304223004336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":213,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2352304223004336"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2023.101150","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2023.101150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101150"}}